Drugs / Immune Globulin Infusion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05513586 | Sep 2022 → Oct 2025 | immunodeficiency disease | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immune Globulin Infusion | “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ |
| Known as | IGI | “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ |
| Route | Subcutaneous | “followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution” NCT05513586 ↗ |